Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14

Cancer Research

Volumn 60, Issue 12, 2000, Pages 3225-3231

  Francisco, Joseph A ^b   Donaldson, Karen L ^a,b   Chace, Dana ^b   Siegall, Clay B ^b   Wahl, Alan F ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; INTERLEUKIN 4; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CD40 LIGAND; CELL DIVISION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIGANDS; LYMPHOMA, B-CELL; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROTEIN BINDING; TIME FACTORS;

EID: 0034047618     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kohler, G., and Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (Lond.), 256: 495-497, 1975.
2. Brown, S. L., Miller, R. A., Horning, S. J., Czerwinski, D., Hart, S. M., McElderry, R., Basham, T., Warnke, R. A., Merigan, T. C., and Levy, R. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with α interferon. Blood, 73: 651-661, 1989.
3. Maloney, D. G., Brown, S., Czerwinski, D. K., Liles, T. M., Hart, S. M., Miller, R. A., and Levy, R. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood, 80: 1502-1510, 1992.
4. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346: 336-340, 1995.
5. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., and Wahl, R. L. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol., 14: 1974-1981, 1996.
6. Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T. M., Dallaire, B. K., Wey, K., Royston, I., Davis, T., and Levy, R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90: 2188-2195, 1997.
7. Leget, G. A., and Czuczman, M. S. Use of Rituximab, the new FDA-approved antibody. Curr. Opin. Oncol., 10: 548-551, 1998.
8. Paulie, S., Ehlin-Henriksson, B., Mellstedt, H., Koho, H., Ben-Aissa, H., and Perlmann, P. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol. Immunother., 20: 23-28, 1985.
9. Banchereau, J., Bazan, F., Blanchard, D., Brière, F., Galizzi, J. P., van Kooten, C., Liu, Y. J., Rousset, F., and Saeland, S. The CD40 antigen and its ligand. Annu. Rev. Immunol., 12: 881-922, 1994.
10. Karmann, K., Hughes, C. C., Schechner, J., Fanslow, W. C., and Pober, J. S. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. USA, 92: 4342-4346, 1995.
11. Ledbetter, J. A., Clark, E. A., Norris, N. A., Shu, G., and Hellström, I. Expression of a functional B-cell receptor CDw40 (Bp50) on carcinomas. In: A. J. McMichael (ed.), Leucocyte Typing III: White Cell Differentiation Antigens, pp. 432-439. Oxford, United Kingdom: Oxford University Press, 1987.
12. Funakoshi, S., Longo, D. L., Beckwith, M., Conley, D. K., Tsarfaty, G., Tsarfaty, I., Armitage, R. J., Fanslow, W. C., Spriggs, M. K., and Murphy, W. J. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood, 83: 2787-2794, 1994.
13. Clark, E. A., and Ledbetter, J. A. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci. USA, 83: 4494-4498, 1986.
14. Uckun, F. M., Gajl-Peczalska, K., Myers, D. E., Jaszcz, W., Haissig, S., and Ledbetter, J. A. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood, 76: 2449-2456, 1990.
15. Maloney, D. G., Donovan, K., and Hamblin, T. J. Antibody therapy for treatment of multiple myeloma. Semin. Hematol., 36 (Suppl. 3): 30-33, 1999.
16. Funakoshi, S., Longo, D. L., and Murphy, W. J. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J. Immunother., 19: 93-101, 1996.
17. Koho, H., Paulie, S., Ben-Aissa, H., Jonsdottir, I., Hansson, Y., Lundblad, M. L., and Perlmann, P. Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence. Cancer Immunol. Immunother., 17: 165-172, 1984.
18. Malik, N., Greenfield, B. W., Wahl, A. F., and Kiener, P. A. Activation of human monocytes through CD40 induces matrix metalloproteinases. J. Immunol., 156: 3952-3960, 1996.
19. Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D., and Boyd, M. R. Evaluation of a soluble tetrazolium/ formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res., 48: 4827-4833, 1988.
20. Ledbetter, J. A., Grosmaire, L. S., Hollenbaugh, D., Aruffo, A., and Nadler, S. G. Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency. Circulatory Shock, 44: 67-72, 1995.
21. Fanslow, W. C., Clifford, K. N., Zappone, J., Alderson, M. R., and Armitage, R. J. CD40 mAbs M2 and M3 inhibit CD40L binding and function. In: S. Schlossman (ed.), Leucocyte Typing V, pp. 555-556. Oxford, UK: Oxford University Press, 1994.
22. Pound, J. D., Challa, A., Holder, M. J., Armitage, R. J., Dower, S. K., Fanslow, W. C., Kikutani, H., Paulie, S., Gregory, C. D., and Gordon, J. Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells. Int. Immunol., 11: 11-20, 1999.
23. Björck, P., and Paulie, S. CD40 antibodies defining distinct epitopes display qualitative differences in their induction of B-cell differentiation. Immunology, 87: 291-295, 1996.
24. Ghetie, M-A., Richardson, J., Tucker, T., Jones, D., Uhr, J. W., and Vitetta, E. S. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int. J. Cancer, 45: 481-485, 1990.
25. Francisco, J. A., Schreiber, G. J., Comereski, C. R., Mezza, L. E., Warner, G. L., Davidson, T. J., Ledbetter, J. A., and Siegall, C. S. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Blood, 89: 4493-4500, 1997.
26. Murphy, W. J., Bennett, M., Anver, M. R., Baseler, M., and Longo, D. L. Human-mouse lymphoid chimeras: host-vs.-graft and graft-vs.-host reactions. Eur. J. Immunol., 22: 1421-1427, 1992.
27. Yao, L., Sgadari, C., Furuke, K., Bloom, E. T., Teruya-Feldstein, J., and Tosato, G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood, 93: 1612-1621, 1999.
28. Grell, M., Zimmermann, G., Gottgried, E., Chen, C. M., Grünwald, U., Huang, D. C. S., Lee, Y. H. W., Dürkop, H., Engelmann, H., Scheurich, P., Wajant, H., and Strasser, A. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J., 18: 3034-3043, 1999.
29. Pullen, S. S., Labadia, M. E., Ingraham, R. H., McWhirter, S. M., Everdeen, D. S., Alber, T., Crute, J. J., and Kehry, M. R. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry, 83: 10168-10177, 1999.
30. Dilloo, D., Brown, M., Roskrow, M., Zhong, W. Holladay, M., Holder, W., and Brenner, M. CD40 ligand induces an antileukemia response in vivo. Blood, 90: 1927-1933, 1997.
31. Hirano, A., Longo, D. L., Taub, D. D., Ferris, D. K., Young, L. S., Eliopoulos, A. G., Agathanggelou, A., Cullen, N., Macartney, J., Fanslow, W. C., and Murphy, W. J. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood, 93: 2999-3007, 1999.
32. Tutt, A. L., French, R. R., Illidge, T. M., Honeychurch, J., McBride, H. M., Penfold, C. A., Fearon, D. T., Parkhouse, R. M. E., Klaus, G. G. B., and Glennie, M. J. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol., 161: 3176-3185, 1998.
33. Younes, A., Snell, V., Consoli, U., Clodi, K., Zhao, S., Palmer, J. L., Thomas, E. K., Armitage, R. J., and Andreeff, M. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br. J. Haematol., 100: 135-141, 1998.
34. McWhirter, S. M., Pullen, S. S., Holton, J. M., Crute, J. J., Kehry, M. R., and Alber, T. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc. Natl. Acad. Sci. USA, 96: 8408-8413, 1999.